Țară: Canada
Limbă: engleză
Sursă: Health Canada
CLODRONATE DISODIUM
HOFFMANN-LA ROCHE LIMITED
M05BA02
CLODRONIC ACID
400MG
CAPSULE
CLODRONATE DISODIUM 400MG
ORAL
120
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0122982001; AHFS:
CANCELLED POST MARKET
2006-10-11
_ _ _ _ _Page 1 of 29_ PRODUCT MONOGRAPH Pr OSTAC ® clodronate disodium for injection 30 mg/mL for slow i.v. infusion only and clodronate disodium capsules 400 mg/capsule Professed Standard Bone Metabolism Regulator Hoffmann-La Roche Ltd. 2455 Meadowpine Boulevard Mississauga, Ontario L5N 6L7 www.rochecanada.com Date of Preparation: June 10, 1998 Date of Revision: June 8, 2005 Submission Control No: 097247 ® Registered Trademark of Hoffmann-La Roche Limited © Copyright 2002 - 2005 Hoffmann-La Roche Limited _ _ _ _ _Page 2 of 29_ Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 ADVERSE REACTIONS....................................................................................................8 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION..............................................................................11 OVERDOSAGE ................................................................................................................13 ACTION AND CLINICAL PHARMACOLOGY ............................................................14 STORAGE AND STABILITY..........................................................................................16 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................16 PART II: SCIENTIFIC INFORMATION ...............................................................................17 PHARMACEUTICAL INFORMATION..........................................................................17 CLINICAL TRIALS................................................................. Citiți documentul complet